In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mini Sentinel Data Covers 126 Million Patients; FDA Weighing Potential Uses For Drug Industry

Executive Summary

With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.

You may also be interested in...



Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA

A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.

Reimbursing Rare Disease Drugs: Getting Away From High Co-Pays

Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.

Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue

Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel